Julien Edeline

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6362419/publications.pdf

Version: 2024-02-01

144 papers	9,882 citations	100601 38 h-index	45040 94 g-index
154 all docs	154 docs citations	154 times ranked	9317 citing authors

#	Article	IF	Citations
1	Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncology, The, 2018, 19, 940-952.	5.1	1,816
2	Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. Journal of Clinical Oncology, 2020, 38, 193-202.	0.8	1,255
3	Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncology, The, 2017, 18, 1624-1636.	5.1	595
4	Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncology, The, 2022, 23, 77-90.	5.1	526
5	CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Annals of Oncology, 2019, 30, v874-v875.	0.6	512
6	Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE) Tj ETQq0 0 0 rgBT /Overlock 10 T 658-667.	0.8	357
7	Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. The Lancet Gastroenterology and Hepatology, 2021, 6, 17-29.	3.7	307
8	Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. Journal of Clinical Oncology, 2019, 37, 1015-1027.	0.8	301
9	Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer, 2012, 118, 147-156.	2.0	250
10	Dosimetry Based on ^{99m}Tc-Macroaggregated Albumin SPECT/CT Accurately Predicts Tumor Response and Survival in Hepatocellular Carcinoma Patients Treated with ⁹⁰Y-Loaded Glass Microspheres: Preliminary Results. Journal of Nuclear Medicine, 2012, 53, 255-263.	2.8	242
11	Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma. JAMA Oncology, 2020, 6, 51.	3.4	176
12	High Prognostic Value of ¹⁸F-FDG PET for Metastatic Gastroenteropancreatic Neuroendocrine Tumors: A Long-Term Evaluation. Journal of Nuclear Medicine, 2014, 55, 1786-1790.	2.8	153
13	Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2019, 37, 4004-4004.	0.8	149
14	Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases. Critical Reviews in Oncology/Hematology, 2010, 73, 246-254.	2.0	144
15	Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond. Cancer Treatment Reviews, 2018, 68, 16-24.	3.4	124
16	Personalized Dosimetry with Intensification Using ⁹⁰Y-Loaded Glass Microsphere Radioembolization Induces Prolonged Overall Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis. Journal of Nuclear Medicine, 2015, 56, 339-346.	2.8	122
17	Clinical impact of 99mTc-MAA SPECT/CT-based dosimetry in the radioembolization of liver malignancies with 90Y-loaded microspheres. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 559-575.	3.3	121
18	Could any pT1a,bN0M0 hormone-responsive, invasive breast carcinomas be safely treated without endocrine therapy?. Journal of Clinical Oncology, 2015, 33, 550-550.	0.8	118

#	Article	IF	Citations
19	Intra-arterial Yttrium-90 Radioembolization Combined with Systemic Chemotherapy is a Promising Method for Downstaging Unresectable Huge Intrahepatic Cholangiocarcinoma to Surgical Treatment. Annals of Surgical Oncology, 2015, 22, 3102-3108.	0.7	111
20	A multicentre comparison between Child Pugh and Albuminâ€Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma. Liver International, 2016, 36, 1821-1828.	1.9	85
21	Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial.. Journal of Clinical Oncology, 2017, 35, 225-225.	0.8	77
22	Volumetric Changes after 90Y Radioembolization for Hepatocellular Carcinoma in Cirrhosis: An Option to Portal Vein Embolization in a Preoperative Setting?. Annals of Surgical Oncology, 2013, 20, 2518-2525.	0.7	76
23	Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 635-643.	3.3	74
24	Current standards and future perspectives in adjuvant treatment for biliary tract cancers. Cancer Treatment Reviews, 2020, 84, 101936.	3.4	73
25	High impact of macroaggregated albuminâ€based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with ⁹⁰Yâ€loaded glass microsphere radioembolization. Liver International, 2017, 37, 101-110.	1.9	71
26	Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma?. British Journal of Cancer, 2010, 103, 1698-1705.	2.9	69
27	Medical treatment for cholangiocarcinoma. Liver International, 2019, 39, 123-142.	1.9	69
28	Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study. Journal of Clinical Oncology, 2022, 40, 262-271.	0.8	59
29	Dosimetric parameters predicting contralateral liver hypertrophy after unilobar radioembolization of hepatocellular carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 392-401.	3.3	58
30	Downstaging with Radioembolization or Chemotherapy for Initially Unresectable Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2020, 27, 3729-3737.	0.7	56
31	Glass Microspheres 90Y Selective Internal Radiation Therapy and Chemotherapy as First-Line Treatment of Intrahepatic Cholangiocarcinoma. Clinical Nuclear Medicine, 2015, 40, 851-855.	0.7	53
32	CAR-T cells and BiTEs in solid tumors: challenges and perspectives. Journal of Hematology and Oncology, 2021, 14, 65.	6.9	50
33	Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: Study protocol for a randomized controlled multicenter phase II/III study. Digestive and Liver Disease, 2019, 51, 318-320.	0.4	49
34	Expression of long non-coding RNA ANRIL predicts a poor prognosis in intrahepatic cholangiocarcinoma. Digestive and Liver Disease, 2019, 51, 1337-1343.	0.4	45
35	Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis. Cancer Treatment Reviews, 2021, 99, 102258.	3.4	45
36	Independent association of PDâ€Ł1 expression with noninactivated VHL clear cell renal cell carcinomaâ€”A finding with therapeutic potential. International Journal of Cancer, 2017, 140, 142-148.	2.3	44

#	Article	IF	Citations
37	Yttrium-90 glass microspheres radioembolization (RE) for biliary tract cancer: a large single-center experience. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 669-676.	3.3	44
38	Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. European Journal of Cancer, 2022, 167, 1-12.	1.3	43
39	Usefulness and pitfalls of MAA SPECT/CT in identifying digestive extrahepatic uptake when planning liver radioembolization. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 872-880.	3.3	40
40	Yttrium-90 Microsphere Radioembolization for Hepatocellular Carcinoma. Liver Cancer, 2015, 4, 16-25.	4.2	40
41	Systemic chemotherapy for hepatocellular carcinoma in non-cirrhotic liver: A retrospective study. World Journal of Gastroenterology, 2009, 15, 713.	1.4	40
42	Prognosis of advanced hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2016, 28, 433-440.	0.8	38
43	Hepatocellular carcinoma in elderly patients: challenges and solutions. Journal of Hepatocellular Carcinoma, 2016, 3, 9.	1.8	36
44	Description of 2 angiogenic phenotypes in clear cell renal cell carcinoma. Human Pathology, 2012, 43, 1982-1990.	1.1	35
45	Non-Alcoholic Steatohepatitis as a Risk Factor for Intrahepatic Cholangiocarcinoma and Its Prognostic Role. Cancers, 2020, 12, 3182.	1.7	34
46	Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial. Clinical Cancer Research, 2022, 28, 2547-2554.	3.2	32
47	Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial. JMIR Research Protocols, 2018, 7, e11234.	0.5	31
48	Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study. Annals of Oncology, 2017, 28, 1612-1617.	0.6	30
49	90Y-Loaded Microsphere SIRT of HCC Patients With Portal Vein Thrombosis: High Clinical Impact of 99mTc-MAA SPECT/CT-Based Dosimetry. Seminars in Nuclear Medicine, 2019, 49, 218-226.	2.5	30
50	KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.. Journal of Clinical Oncology, 2018, 36, 209-209.	0.8	30
51	Systemic treatment of hepatocellular carcinoma: standard of care in China and elsewhere. Lancet Oncology, The, 2020, 21, 479-481.	5.1	29
52	Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Childâ€“Pugh B cirrhosis. Hepatology International, 2021, 15, 93-104.	1.9	28
53	Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib. Liver International, 2020, 40, 215-228.	1.9	27
54	Cementoplasty for painful bone metastases: a series of 42 cases. Medical Oncology, 2012, 29, 1378-1383.	1.2	26

#	Article	IF	Citations
55	Extended liver resections for intrahepatic cholangiocarcinoma: Friend or foe?. Surgery, 2015, 157, 656-665.	1.0	26
56	Adjuvant capecitabine in biliary tract cancer: a standard option?. Lancet Oncology, The, 2019, 20, 606-608.	5.1	26
57	A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and 90Y-loaded glass microsphere selective internal radiation therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1731-1741.	3.3	25
58	Ki-67 index and response to chemotherapy in patients with neuroendocrine tumours. Endocrine-Related Cancer, 2016, 23, 563-570.	1.6	24
59	Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinumâ€“gemcitabine regimen. European Journal of Cancer, 2012, 48, 1141-1146.	1.3	23
60	Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors. Cancer Chemotherapy and Pharmacology, 2015, 75, 215-219.	1.1	23
61	Comparison of Choi criteria and Response Evaluation Criteria in Solid Tumors (RECIST) for intrahepatic cholangiocarcinoma treated with glass-microspheres Yttrium-90 selective internal radiation therapy (SIRT). European Journal of Radiology, 2016, 85, 1445-1452.	1.2	23
62	Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study. Digestive and Liver Disease, 2017, 49, 692-696.	0.4	23
63	An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma. Expert Opinion on Pharmacotherapy, 2017, 18, 1467-1476.	0.9	23
64	Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort. World Journal of Gastroenterology, 2017, 23, 2545.	1.4	21
65	TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLC. CardioVascular and Interventional Radiology, 2022, 45, 1599-1607.	0.9	21
66	Aortic dissection in a patient treated by sunitinib for metastatic renal cell carcinoma. Annals of Oncology, 2010, 21, 186-187.	0.6	20
67	A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumors. Investigational New Drugs, 2013, 31, 900-909.	1.2	20
68	Synchronous Metastatic Clear-Cell Renal Cell Carcinoma: A Distinct Morphologic, Immunohistochemical, and Molecular Phenotype. Clinical Genitourinary Cancer, 2017, 15, e1-e7.	0.9	20
69	Healthâ€related qualityâ€ofâ€life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTEâ€240. Cancer, 2021, 127, 865-874.	2.0	20
70	Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score. European Journal of Cancer, 2017, 86, 135-142.	1.3	19
71	Prevalence of Proton Pump Inhibitor Use Among Patients With Cancer. JAMA Network Open, 2021, 4, e2113739.	2.8	19
72	A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	3.5	17

#	Article	IF	Citations
73	Negative phase 3 study of 90 Y microspheres versus sorafenib in HCC. Lancet Oncology, The, 2018, 19, e70.	5.1	16
74	ALBI Score Is a Strong Predictor of Toxicity Following SIRT for Hepatocellular Carcinoma. Cancers, 2021, 13, 3794.	1.7	16
75	Occupational radiation exposure of medical staff performing 90Y-loaded microsphere radioembolization. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 824-831.	3.3	15
76	52P Modified FOLFIRINOX versus CISGEM as first-line chemotherapy for advanced biliary tract cancer: Results of AMEBICA PRODIGE 38 randomized phase II trial. Annals of Oncology, 2020, 31, S260-S261.	0.6	15
77	Preliminary results of the Phase 1 Lip-Re I clinical trial: biodistribution and dosimetry assessments in hepatocellular carcinoma patients treated with 188Re-SSS Lipiodol radioembolization. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1506-1517.	3.3	15
78	A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers. Targeted Oncology, 2017, 12, 655-661.	1.7	14
79	Association of Antiâ€“Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma. JAMA Dermatology, 2020, 156, 982.	2.0	14
80	Implementation of a Nurse-driven Educational Program Improves Management of Sorafenibâ€™s Toxicities in Hepatocellular Carcinoma. Cancer Nursing, 2018, 41, 418-423.	0.7	13
81	Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. Clinical Colorectal Cancer, 2019, 18, e394-e401.	1.0	13
82	Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma. Liver Cancer, 2022, 11, 460-473.	4.2	13
83	Incidence of brain metastases in HER2+ gastric or gastroesophageal junction adenocarcinoma. Acta OncolÃ³gica, 2015, 54, 1833-1835.	0.8	12
84	Lymphocytes and Neutrophil-to-Lymphocyte Ratio Variations After Selective Internal Radiation Treatment for HCC: A Retrospective Cohort Study. CardioVascular and Interventional Radiology, 2020, 43, 1175-1181.	0.9	12
85	Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies. European Journal of Cancer, 2022, 164, 80-87.	1.3	12
86	Increased thyroid uptake on 18F-FDG PET/CT is associated with the development of permanent hypothyroidism in stage IV melanoma patients treated with anti-PD-1 antibodies. Cancer Immunology, Immunotherapy, 2021, 70, 679-687.	2.0	11
87	Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy. Expert Opinion on Therapeutic Targets, 2021, 25, 153-162.	1.5	11
88	Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines. Journal of Cancer Research and Clinical Oncology, 2012, 138, 907-916.	1.2	10
89	Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240. Annals of Oncology, 2019, 30, iv135-iv136.	0.6	10
90	FOLFIRINOX Deâ€Escalation in Advanced Pancreatic Cancer: A Multicenter Realâ€Life Study. Oncologist, 2020, 25, e1701-e1710.	1.9	10

#	Article	IF	Citations
91	How to assess the efficacy or failure of targeted therapy: Deciding when to stop sorafenib in hepatocellular carcinoma. World Journal of Hepatology, 2016, 8, 1541.	0.8	10
92	78TiP KEYNOTE-966 trial in progress: Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer. Annals of Oncology, 2020, 31, S270-S271.	0.6	9
93	Implementation of a molecular tumor board at a regional level to improve access to targeted therapy. International Journal of Clinical Oncology, 2020, 25, 1234-1241.	1.0	9
94	Liver transarterial chemoembolization and sunitinib for unresectable hepatocellular carcinoma: Results of the PRODIGE 16 study. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101464.	0.7	9
95	Pembrolizumab (pembro) in patients with advanced hepatocellular carcinoma (HCC): KEYNOTE-224 update.. Journal of Clinical Oncology, 2018, 36, 4020-4020.	0.8	9
96	Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network. Gynecologic Oncology, 2020, 158, 666-672.	0.6	8
97	Prognostic impact of thyroid dysfunctions on progression-free survival in patients with metastatic melanoma treated with anti-PD-1 antibodies. Melanoma Research, 2021, 31, 208-217.	0.6	8
98	Haemolytic uremic syndrome and gemcitabine: Jaundice is not always progression in cholangiocarcinoma. Acta OncolÃ³gica, 2012, 51, 687-688.	0.8	7
99	High Impact of Preferential Flow on ^{99m}Tc-MAA and ⁹⁰Y-Loaded Microsphere Uptake Correlation. Journal of Nuclear Medicine, 2016, 57, 1829-1830.	2.8	7
100	Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials. Expert Opinion on Investigational Drugs, 2021, 30, 975-983.	1.9	7
101	Targeted Therapies for Perihilar Cholangiocarcinoma. Cancers, 2022, 14, 1789.	1.7	7
102	Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 48-54.	0.7	6
103	Long-Term Use of Proton Pump Inhibitors in Cancer Patients: An Opinion Paper. Cancers, 2022, 14, 1156.	1.7	6
104	Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability. Journal of Vascular and Interventional Radiology, 2015, 26, 1874-1878.e2.	0.2	5
105	mRECIST for systemic therapies: More evidence is required before recommendations can be made. Journal of Hepatology, 2017, 67, 195.	1.8	5
106	Adverse events of targeted therapies reported by patients with cancer treated in primary care. European Journal of General Practice, 2020, 26, 202-209.	0.9	5
107	Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study. British Journal of Cancer, 2022, 126, 1394-1400.	2.9	5
108	Patientsâ€™ Experience of Systemic Treatment of Hepatocellular Carcinoma: A Review of the Impact on Quality of Life. Cancers, 2022, 14, 179.	1.7	5

#	Article	IF	Citations
109	Adjuvant GEMOX for biliary tract cancer: Updated relapse-free survival and first overall survival results of the randomized PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial. Annals of Oncology, 2017, 28, v617.	0.6	4
110	Streamlining TARE or personalizing SIRT? Different philosophies to treat different HCCs with Yttrium-90â€¦. Journal of Hepatology, 2020, 72, 1046-1048.	1.8	4
111	FOLFIRINOX relative dose intensity and disease control in advanced pancreatic adenocarcinoma. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110298.	1.4	4
112	Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma. Clinical Therapeutics, 2021, 43, 1201-1212.	1.1	4
113	Selective internal radiation therapy in older patients with hepatocellular carcinoma: a retrospective analysis. European Journal of Gastroenterology and Hepatology, 2022, 34, 417-421.	0.8	4
114	Loss of SMARCB1 expression in colon carcinoma. Cancer Biomarkers, 2020, 27, 399-406.	0.8	4
115	FFCD 1709-SIRTCI phase II trial: Selective internal radiation therapy plus Xelox, Bevacizumab and Atezolizumab in liver-dominant metastatic colorectal cancer. Digestive and Liver Disease, 2022, 54, 857-863.	0.4	4
116	PDL-1 and PDL1 expressions in clear cell renal cell carcinoma (ccRCC) of metastatic patients with sunitinib first-line treatment.. Journal of Clinical Oncology, 2015, 33, e14002-e14002.	0.8	3
117	Evaluating the Effectiveness of Yttrium-90 Glass Microspheres in the Treatment of Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, and Metastatic Colorectal Cancer in Practice: Protocol for the Prospective PROACTIF Phase IV Registry Study in France. CardioVascular and Interventional Radiology, 2022, 45, 1-11.	0.9	3
118	In vitro demonstration of synergy/additivity between (188)rhenium and sorafenib on hepatoma lines: preliminary results. Anticancer Research, 2013, 33, 3871-7.	0.5	3
119	Abscopal Effect After SIRT: It Exists, but How Could We Use It?. CardioVascular and Interventional Radiology, 2020, 43, 1650-1651.	0.9	2
120	Integrative genomics highlights opportunities for innovative therapies targeting the tumor microenvironment in gallbladder cancer. Journal of Hepatology, 2021, 74, 1018-1020.	1.8	2
121	Combined hepatocellularâ€cholangiocarcinoma â€“ More questions than answers. Liver International, 2021, 41, 1186-1188.	1.9	2
122	Predictive Factors of Chemotherapy Initiation after Biliary Drainage for Advanced Biliary Tract Cancer: A Retrospective Multicenter Study. Journal of Gastrointestinal and Liver Diseases, 2021, 30, 254-258.	0.5	2
123	Safety and Efficacy of Sorafenib in Renal Cell Carcinoma. Cancer Growth and Metastasis, 2012, 5, CGM.S7526.	3.5	1
124	Reply: Modifying the Poor Prognosis Associated with ¹⁸F-FDGâ€“Avid NET with Peptide Receptor Chemo-Radionuclide Therapy (PRCRT). Journal of Nuclear Medicine, 2015, 56, 969-969.	2.8	1
125	Does Y90 Radioembolization Prolong Overall Survival Compared With Chemoembolization in Patients With Hepatocellular Carcinoma?. Gastroenterology, 2017, 152, 1624-1625.	0.6	1
126	PD-6 Gemcitabine + nab-paclitaxel or gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: A population-based, multicenter AGEO study. Annals of Oncology, 2020, 31, S213-S214.	0.6	1

#	Article	IF	Citations
127	Efficacy and safety of panitumumab in a cohort of patients with metastatic colorectal cancer in France: PANI OUEST, a postâ€“EMA-approval descriptive study with a geriatric oncology focus. Turkish Journal of Gastroenterology, 2020, 31, 695-705.	0.4	1
128	Analysis of medical practices for French patients with BRAF mutant metastatic colorectal cancer.. Journal of Clinical Oncology, 2016, 34, e15070-e15070.	0.8	1
129	Selective Internal Radiation Combined with Chemotherapy Maintains the Quality of Life in Intrahepatic Cholangiocarcinomas. Current Oncology, 2021, 28, 4530-4541.	0.9	1
130	MiR-31-3p do not predict anti-EGFR efficacy in first-line therapy of RAS wild-type metastatic right-sided colon cancer. Clinics and Research in Hepatology and Gastroenterology, 2022, , 101888.	0.7	1
131	Capecitabine: Still a Standard Option in the Adjuvant Setting of Biliary Tract Cancer?. Journal of Clinical Oncology, 0, , .	0.8	1
132	THE PROGNOSIC IMPORTANCE OF ANGIOGENIC PHENOTYPE IN RENAL CELL CARCINOMA. Journal of Urology, 2009, 181, 111-111.	0.2	0
133	Sorafenibâ€•or 90Yâ€‐loaded resin microsphere radioembolization for locally advanced hepatocellular carcinoma, what should we trust?. Liver International, 2015, 35, 1779-1780.	1.9	0
134	Hilar fat infiltration: A new prognostic factor in metastatic clear cell renal cell carcinoma with first-line sunitinib treatment. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 603.e7-603.e14.	0.8	0
135	Need for a stratified analysis in stage I malignant ovarian germ cell tumors (MOGCT): Prospective survival analysis of cases collection from the French rare malignant ovarian tumors (TMRO) network & GINECO group. Annals of Oncology, 2018, 29, viii335.	0.6	0
136	MON-PO377: Are Body Composition Parameters Associated with the Clinical Outcome of Patients with Advanced Pancreatic Cancer Receiving Fluoropyrimidine-Based Chemotherapy?. Clinical Nutrition, 2019, 38, S198.	2.3	0
137	TGF-beta-associated circular RNAs in cholangiocarcinoma: mechanisms and biomarkers. Journal of Hepatology, 2020, 73, S632-S633.	1.8	0
138	1011P The experience associated with caregiving for patients with intermediate stage hepatocellular carcinoma (HCC) receiving transcatheter arterial chemoembolisation (TACE) treatment. Annals of Oncology, 2020, 31, S700-S701.	0.6	0
139	1531P FOLFIRINOX relative dose intensity (RDI) and disease control in advanced pancreatic cancer patients (APC). Annals of Oncology, 2020, 31, S942-S943.	0.6	0
140	ASO Author Reflections: Intrahepatic Cholangiocarcinoma: Downstaging Strategies Open the Gate to Surgery and Cure. Annals of Surgical Oncology, 2020, 27, 3738-3739.	0.7	0
141	Looking for synergy or additivity between 188Re and sorafenib on hepatoma cell lines.. Journal of Clinical Oncology, 2012, 30, 247-247.	0.8	0
142	Incidence of brain metastases in HER2+ gastric or esogastric junction adenocarcinoma.. Journal of Clinical Oncology, 2013, 31, 126-126.	0.8	0
143	An easy-to-use nomogram to predict overall survival (OS) at 6 months after initiation of FOLFIRINOX first-line chemotherapy in patients (pts) with metastatic pancreatic cancer (mPC).. Journal of Clinical Oncology, 2018, 36, 394-394.	0.8	0
144	Tivozanib for hepatocellular carcinoma: not likely a new option. Annals of Translational Medicine, 2020, 8, 1337-1337.	0.7	0